MD Anderson Cancer Center: Combination Biomarker Predicts Response to Immune Checkpoint Therapy in Patients With Advanced Bladder Cancer
June 18, 2020
June 18, 2020
HOUSTON, Texas, June 18 -- The University of Texas's MD Anderson Cancer Center issued the following news release on June 17:
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors, according to researchers from The University of Texas MD Anderson Cancer Center.
The study, published today in Science . . .
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors, according to researchers from The University of Texas MD Anderson Cancer Center.
The study, published today in Science . . .